- Home
- BST vs ELVN Comparison
BST vs ELVN Comparison
Compare BST & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BST
- ELVN
- Stock Information
- Founded
- BST 2014
- ELVN 2016
- Country
- BST United States
- ELVN United States
- Employees
- BST N/A
- ELVN N/A
- Industry
- BST Finance Companies
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- BST Finance
- ELVN Health Care
- Exchange
- BST Nasdaq
- ELVN Nasdaq
- Market Cap
- BST 1.3B
- ELVN 1.2B
- IPO Year
- BST N/A
- ELVN 2020
- Fundamental
- Price
- BST $38.84
- ELVN $20.07
- Analyst Decision
- BST
- ELVN Strong Buy
- Analyst Count
- BST 0
- ELVN 5
- Target Price
- BST N/A
- ELVN $41.20
- AVG Volume (30 Days)
- BST 88.5K
- ELVN 435.9K
- Earning Date
- BST 01-01-0001
- ELVN 08-12-2025
- Dividend Yield
- BST 7.72%
- ELVN N/A
- EPS Growth
- BST N/A
- ELVN N/A
- EPS
- BST N/A
- ELVN N/A
- Revenue
- BST N/A
- ELVN N/A
- Revenue This Year
- BST N/A
- ELVN N/A
- Revenue Next Year
- BST N/A
- ELVN N/A
- P/E Ratio
- BST N/A
- ELVN N/A
- Revenue Growth
- BST N/A
- ELVN N/A
- 52 Week Low
- BST $27.87
- ELVN $13.30
- 52 Week High
- BST $39.59
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- BST 63.62
- ELVN 43.84
- Support Level
- BST $38.25
- ELVN $21.25
- Resistance Level
- BST $39.13
- ELVN $22.83
- Average True Range (ATR)
- BST 0.33
- ELVN 1.45
- MACD
- BST -0.02
- ELVN -0.26
- Stochastic Oscillator
- BST 73.66
- ELVN 6.91
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.